抗病毒药物研发应对 COVID-19 大流行。
Antiviral Drug Discovery To Address the COVID-19 Pandemic.
机构信息
University of California San Diego, Distinguished Professor of Pathology and Medicine (Active Emeritus), Director, The HIV Institute, Co-Director, San Diego Center for AIDS Research, Florence Seeley Riford Chair in AIDS Research (Emeritus), La Jolla, California, USA
出版信息
mBio. 2020 Sep 25;11(5):e02134-20. doi: 10.1128/mBio.02134-20.
Abstract
The magnitude of the morbidity and mortality inflicted upon the global population in less than 1 year has driven the inescapable conclusion that the discovery and development of effective antiviral drugs for COVID-19 are urgent and should be prioritized. The antiviral drug discovery programs that emerged for HIV and hepatitis C virus have enabled technology and expertise to accelerate this process for SARS-CoV-2. The description of candidate lead inhibitors for the viral main protease (M) exemplifies this accelerated approach and reminds us of the needs and opportunities for addressing this pandemic.
摘要
在不到 1 年内，全球人口所遭受的发病率和死亡率之高，不可避免地得出结论，即发现和开发针对 COVID-19 的有效抗病毒药物是紧迫的，应该优先考虑。针对 HIV 和丙型肝炎病毒的抗病毒药物发现计划使技术和专业知识能够加速这一针对 SARS-CoV-2 的进程。病毒主要蛋白酶 (M) 的候选先导抑制剂的描述就是这种加速方法的范例，提醒我们需要并提供了解决这一大流行病的机会。
相似文献
1
Antiviral Drug Discovery To Address the COVID-19 Pandemic.
mBio. 2020 Sep 25;11(5):e02134-20. doi: 10.1128/mBio.02134-20.
2
Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL Reporter Assay.
J Virol. 2020 Oct 27;94(22). doi: 10.1128/JVI.01265-20.
3
Optimization Rules for SARS-CoV-2 M Antivirals: Ensemble Docking and Exploration of the Coronavirus Protease Active Site.
Viruses. 2020 Aug 26;12(9):942. doi: 10.3390/v12090942.
4
In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
Molecules. 2020 May 29;25(11):2529. doi: 10.3390/molecules25112529.
5
Biochemical screening for SARS-CoV-2 main protease inhibitors.
PLoS One. 2020 Oct 6;15(10):e0240079. doi: 10.1371/journal.pone.0240079. eCollection 2020.
6
Discovery of potent inhibitors for SARS-CoV-2's main protease by ligand-based/structure-based virtual screening, MD simulations, and binding energy calculations.
Phys Chem Chem Phys. 2020 Oct 21;22(40):23099-23106. doi: 10.1039/d0cp04326e.
7
Structural-based virtual screening and in vitro assays for small molecules inhibiting the feline coronavirus 3CL protease as a surrogate platform for coronaviruses.
Antiviral Res. 2020 Oct;182:104927. doi: 10.1016/j.antiviral.2020.104927. Epub 2020 Sep 7.
8
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Tohoku J Exp Med. 2020 May;251(1):27-30. doi: 10.1620/tjem.251.27.
9
Clean Grinding Technique: A Facile Synthesis and In Silico Antiviral Activity of Hydrazones, Pyrazoles, and Pyrazines Bearing Thiazole Moiety against SARS-CoV-2 Main Protease (M).
Molecules. 2020 Oct 6;25(19):4565. doi: 10.3390/molecules25194565.
10
Coronavirus diseases and pregnancy: COVID-19,SARS, and MERS.
Przegl Epidemiol. 2020;74(2):276-289. doi: 10.32394/pe.74.21.
引用本文的文献
1
Darunavir ethanolate: Repurposing an anti-HIV drug in COVID-19 treatment.
Eur J Med Chem Rep. 2021 Dec;3:100013. doi: 10.1016/j.ejmcr.2021.100013. Epub 2021 Oct 22.
2
Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters.
J Virol. 2022 Feb 23;96(4):e0155121. doi: 10.1128/JVI.01551-21. Epub 2021 Nov 24.
3
The New Generation DHODH Inhibitor MEDS433 Hinders the In Vitro Replication of SARS-CoV-2 and Other Human Coronaviruses.
Microorganisms. 2021 Aug 14;9(8):1731. doi: 10.3390/microorganisms9081731.
4
Existing Drugs Considered as Promising in COVID-19 Therapy.
Int J Mol Sci. 2021 May 21;22(11):5434. doi: 10.3390/ijms22115434.
本文引用的文献
1
GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.
mBio. 2020 Aug 20;11(4):e01833-20. doi: 10.1128/mBio.01833-20.
2
Dexamethasone in Hospitalized Patients with Covid-19.
N Engl J Med. 2021 Feb 25;384(8):693-704. doi: 10.1056/NEJMoa2021436. Epub 2020 Jul 17.
3
The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?
Cell Host Microbe. 2020 Jun 10;27(6):863-869. doi: 10.1016/j.chom.2020.05.009. Epub 2020 May 20.
4
Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial.
Lancet. 2020 May 30;395(10238):1695-1704. doi: 10.1016/S0140-6736(20)31042-4. Epub 2020 May 10.
5
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease.
Science. 2020 Jun 19;368(6497):1331-1335. doi: 10.1126/science.abb4489. Epub 2020 Apr 22.
6
An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice.
Sci Transl Med. 2020 Apr 29;12(541). doi: 10.1126/scitranslmed.abb5883. Epub 2020 Apr 6.
7
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Cell. 2020 Apr 16;181(2):271-280.e8. doi: 10.1016/j.cell.2020.02.052. Epub 2020 Mar 5.
8
Safety, pharmacokinetics and antiviral activity of AT-527, a novel purine nucleotide prodrug, in HCV-infected subjects with and without cirrhosis.
Antimicrob Agents Chemother. 2019 Sep 9;63(12). doi: 10.1128/AAC.01201-19. Epub 2019 Sep 30.
9
2'-Deoxy-4'-C-ethynyl-2-fluoroadenosine: a nucleoside reverse transcriptase inhibitor with highly potent activity against all HIV-1 strains, favorable toxic profiles and stability in plasma.
Nucleic Acids Symp Ser (Oxf). 2006(50):1-2. doi: 10.1093/nass/nrl001.
10
Novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI) UIC-94017 (TMC114) with potent activity against multi-PI-resistant human immunodeficiency virus in vitro.
Antimicrob Agents Chemother. 2003 Oct;47(10):3123-9. doi: 10.1128/AAC.47.10.3123-3129.2003.
Zotero 插件